Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open Label, Randomized Study of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02808208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02808208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open Label, Randomized Study of Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 7, 2017
Completion date
December 31, 2026
Enrollment
74 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage renal disease (esrd), vascular access complication